Navigation Links
Cancer Care Compromised by Cost

A team of researchers has recommended that, in order to implement better cancer care to patients certain reforms have to be mustered immediately. //Their views were published in the British Medical journal. The team of researchers opined that the National Institute for Health and Clinical Excellence (NICE) should amend some of their modes of action, in order to cater to the immediate needs of cancer patients. More planning is essential to ensure that those battling with cancer shall be assured supply of life saving drugs through the NHS.

Last August NICE, had pointed that unless local Trusts mobilized funds, they would be unable to cover the entire costs of drugs like Herceptin to patients. Herceptin is a drug that can fight cancer by targeting a protein, the HER2 protein, which can trigger off tumors. Almost 20% of breast cancers are noted to be HER2 positive. NICE has ruled that, all breast cancer patients that are HER2 would benefit from treatment with Herpecitin following chemotherapy, surgery or radiation therapy. However following this ruling, no move has been made by NICE to indicate where the extra funds should be recovered from. Unless federal funds are released, cancer patient who cannot afford the treatment cannot get the benefits.

Doctors from Norwich University Hospital NHS Trust studied the data linked to the bulk of cancer patients receiving treatment at their hospital. Their findings show that 1.9 million pounds are required to make the drug Herpecitin available to all patients who need the drug. Costs cannot be contained with the treatment alone. The projected expense can be covered only if the equally important palliative care or chemotherapy is done away with, they concluded.

There is no conclusive data that shows that there are any long term benefits that the drug Herpecetin, promises except that it is the drug of choice at this moment. That is not a reliable reason to deny patients conventional treatment and sw itch over to Herpecitin, which is not cost effective either, say doctors.

Doctors who were part of the study opine that, in an ideal situation the government should back up their decision by providing the source of funding for newer drugs. Suggestions have been framed, urging the Department of Health to keep aside money to fund NICE.
MST
'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: